Table 2 Prognostic value of SLC6A1 expression for the biochemical recurrence-free in univariate and multivariate analyses using Cox Regression models
From: Overexpression of SLC6A1 associates with drug resistance and poor prognosis in prostate cancer
| Â | Univariable Analysis | P | Multivariable Analysis | P |
|---|---|---|---|---|
HR(95%CI) | HR(95%CI) | |||
Age (< 66 vs. ≥6a6) | 1.02 (0.575–1.820) | 0.938 | 0.711 (0.373–1.356) | 0.301 |
Gleason score (< 8 vs. ≥8) | 3.927(2.182–7.070) | 0.0001 | 2.619(1.344–5.106) | 0.005 |
Pathological tumor stage (T2 vs. ≥T3) | 4.800(2.060–11.185) | 0.0001 | 2.092(0.826–5.299) | 0.120 |
Clinical tumor stage (<T2A vs. ≥T2A) | 3.289(1.647–6.568) | 0.001 | 2.328(1.134–4.777) | 0.021 |
SLC6A1 (high vs. low) | 2.190(1.273–3.767) | 0.005 | 1.751(0.977–3.138) | 0.060 |